Ebola research in Congo still seeks effective treatment
An international study is under way, but no approved treatment yet exists for the Bundibugyo variant.
A clinical study into treatments for the Bundibugyo variant of the Ebola virus is under way in Congo. The World Health Organization stresses that there is still no specifically approved medicine or vaccine against this variant.
The PARTNERS study began enrolling patients on 2 July. According to the WHO, the research is being conducted at five treatment centres in Ituri province. By 7 September, more than three hundred confirmed patients had been enrolled in the study.
The research is taking place during a major outbreak. A WHO report counted 6,778 confirmed cases of the Bundibugyo variant worldwide on 7 September, including 6,757 in the Democratic Republic of Congo, Uganda and one case in France. A total of 3,269 deaths had been reported.
The figures have since risen further. On 28 September, Associated Press reported that Congo alone had recorded more than 8,000 confirmed cases. These figures are not directly comparable with the WHO overview of 7 September, because they use different reporting dates and possibly updated records.
The variant differs from the Zaire variant, for which the Ervebo vaccine was developed. The WHO advises using Ervebo for Bundibugyo only within a research protocol, because its effectiveness against this variant in humans has not yet been established.
Vaccines are also being investigated alongside the study into treatments. The WHO describes the research as an attempt to gather reliable data quickly during the outbreak. This is scientifically and practically complicated: patients must be found, research teams must be able to work safely and treatment centres are facing staff shortages.
The race for evidence does not change the uncertainty facing patients. A drug that appears promising in laboratory research or against another Ebola variant is not thereby a proven treatment for Bundibugyo. The WHO therefore continues to stress rapid diagnosis, good supportive care, infection prevention and cooperation with local communities.
One story, several perspectives
What is established
- The Bundibugyo variant has no approved specific vaccine or medicine.
- The PARTNERS study is investigating treatments during the outbreak.
- The WHO advises using Ervebo for this variant only within research.
- Outbreak figures differ depending on the reporting date and registration method.
Left
Arguments A serious outbreak justifies rapid international funding, broad access to research and strong public health services. Communities in the affected area should help determine how research and care are organised.
Values Equality, solidarity and access to healthcare.
Consequences More public funding and open collaboration could speed up research, but would also require sustained commitment after media attention fades.
Centre
Arguments Research must be conducted quickly, but according to protocols that safeguard safety, consent and reliable comparison. International organisations and the Congolese authorities must divide responsibilities and data sharing clearly.
Values Scientific reliability, proportionality and institutional trust.
Consequences A careful approach may delay the outcome, but reduces the risk that unproven treatments undermine confidence in the response.
Right
Arguments The outbreak shows that countries themselves must be better able to respond and that international aid should be deployed in a targeted way. From this perspective, faster approval of promising treatments may be justified when the risks are made transparent.
Values Responsibility, decisiveness and national resilience.
Consequences More scope for emergency approval could give patients faster access, but increases the risk that effectiveness and side effects remain insufficiently clear.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The text uses the WHO as its primary source for the study, the virus variant and the uncertainty surrounding treatments. The later AP figures have been kept separate from the earlier WHO reporting date and are not presented as a directly comparable series.
- confirmed The PARTNERS study began on 2 July and had more than three hundred participants by 7 September. — The WHO gives the start date, five centres and more than three hundred enrolled patients. source
- confirmed There is no approved specific vaccine or medicine against Bundibugyo. — This is stated on the WHO situation page about the outbreak. source
- confirmed The WHO advises using Ervebo against Bundibugyo only within research. — The WHO reports that its effectiveness against this variant in humans is unknown. source
- confirmed The WHO counted 6,778 confirmed cases worldwide on 7 September. — This is the explicit figure reported at that date in the WHO report. source
- confirmed Associated Press reported more than 8,000 confirmed cases in Congo on 28 September. — AP reported this later figure and linked it to statements by officials. source
Editor's note
The study and the status of vaccines and treatments were checked against the WHO. The latest figures differ by reporting date and source; these differences have therefore been stated explicitly.Sources
- Ebola disease caused by Bundibugyo virus – Democratic Republic of the Congo — World Health Organization
- Ongoing outbreak in the Democratic Republic of the Congo — WHO Regional Office for Africa
- Congo's Ebola outbreak tops 8,000 confirmed cases as disease remains out of control — Associated Press
More on this in Dutch media
- RTL Nieuws — „ebola congo”
- NOS — „ebola congo”
- Het Parool — „ebola congo”